Engineered LC3 could make autophagy more programmable, giving researchers greater control over the cell-cleansing pathway. The CSIR-IGIB-led study explores its potential as a therapeutic platform for cancer and neurodegenerative diseases.
India powers primary care through 1.86 lakh Ayushman Arogya Mandirs, delivering 420 million screenings and expanding preventive healthcare nationwide.
Long-acting immunology antibodies are central to Sanofi and Regeneron's expanded alliance, with USD 1 billion upfront and up to USD 7 billion in milestones as they build beyond Dupixent.
The latest updates highlight three strong mid-stage results in the pharma pipeline, as Eli Lilly, Merck, and AbbVie advance promising therapies toward Phase 3 trials.
Pharma pricing faces tighter scrutiny this month as courts, state regulators and global agreements target drug, device and hospital supply-chain markups.
Wegovy pill users switching from injectable GLP-1 drugs lost 4.1 percent of their body weight in three months, highlighting a potential new pathway for treatment continuity.
Biodeal's 135 million-unit acquisition of Biological E’s sterile injectable facility highlights India’s intensifying CDMO capacity scramble.
Digital health is becoming central to BRICS healthcare as AI, telemedicine and interoperable health records expand access, especially across India's rural and remote regions.
India's healthcare capacity is expanding as Global Health invests Rs 165.82 crore in land for a 350-plus-bed Medanta hospital in Ghaziabad, adding to the country's organised healthcare infrastructure.
India is positioned to gain as the US zeroes tariffs on key specialty drugs, creating new opportunities for Indian pharma manufacturers.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
